Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | Acute leukemia research at LMU Munich

Wolfgang Hiddemann • 14 Mar 2019
ISAL 2019
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Wolfgang Hiddemann, MD, PhD, discusses acute leukemia research at his institute, LMU Hospital Munich, Munich, Germany. He also discusses the recent approval of the hospital as a CAR T-cell treatment center. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Wolfgang Hiddemann

ISAL 2023: looking forward to this year’s meeting and insights into the program 3:08
ISAL 2023: looking forward to this year’s meeting and insights into the program
Wolfgang Hiddemann • 16 Mar 2023
International Symposium on Acute Leukemias: key messages from the 2019 meeting 2:52
International Symposium on Acute Leukemias: key messages from the 2019 meeting
Wolfgang Hiddemann • 15 Mar 2019
Challenging the norms for elderly AML treatment: clinical trials & intensive therapy 8:26
Challenging the norms for elderly AML treatment: clinical trials & intensive therapy
Alan Burnett et al. • 17 Feb 2018
Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy 11:35
Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
Alan Burnett et al. • 2 Mar 2018

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals